Seaport Therapeutics (SPTX) Stock Price, News & Analysis

Company Overview

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company is working to advance treatments for conditions in areas such as psychiatry and neurology, with the goal of addressing significant limitations associated with existing therapies.

Seaport’s drug-development efforts are supported by its proprietary Glyph platform, which is designed to enable oral delivery of therapeutics that have historically required injection or infusion. The platform is intended to improve the convenience and potential clinical utility of certain medicines, while supporting the development of a pipeline of novel CNS treatments.

Seaport Therapeutics was established with backing from PureTech Health and is led by Chief Executive Officer Daphne Zohar. The company is headquartered in the United States and is conducting research and clinical development aimed at serving patients with CNS disorders in the U.S. and other global markets.

Key Stats

• Today's Range: $21.45 to $22.44
• 50-Day Range: $19.74 to $27.84
• 52-Week Range: $14.85 to $28.38
• Volume: 192,796 shs
• Average Volume: 256,833 shs
• Market Capitalization: $1.15 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.57
• Consensus Rating: Moderate Buy

Seaport Therapeutics Stock Analysis - MarketRank™

Seaport Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 224th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Seaport Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 6 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Seaport Therapeutics has a consensus price target of $38.57, representing about 79.2% upside from its current price of $21.52.

Amount of Analyst Coverage

Seaport Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Seaport Therapeutics are expected to grow in the coming year, from ($4.60) to ($2.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Seaport Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Seaport Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.88% of the float of Seaport Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Seaport Therapeutics has a short interest ratio ("days to cover") of 20.69, which indicates bearish sentiment.

Change versus previous month

Short interest in Seaport Therapeutics has recently decreased by 0.11%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Seaport Therapeutics does not currently pay a dividend.

Dividend Growth

Seaport Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.27

News Sentiment

Seaport Therapeutics has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Seaport Therapeutics this week, compared to 2 articles on an average week.

Search Interest

14 people have searched for SPTX on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Seaport Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Seaport Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/03/2026
• Today: 9/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SPTX
• CIK: 2042347
• Web: www.seaporttx.com
• Phone: 617-807-4062
• Fax: N/A
• Employees: 58
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Seaport Therapeutics: $38.57
• High Price Target: $50.00
• Low Price Target: $30.00
• Potential Upside/Downside: +79.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.00
• Quick Ratio: 18.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,530,000
• Free Float: N/A
• Market Cap: $1.15 billion
• Optionable: N/A
• Beta: N/A